Fauci Files: What counts as “gain of function” in oversight
The July 2026 Senate release of Anthony Fauci’s records contains a direct proposal for how future oversight should name the research it intends to regulate. The document states that “gain of function” in proposed legislation is meant to cover work that could increase transmissibility or virulence in a potential pandemic pathogen, and it recommends replacing the shorthand with the clearer phrase “pathogen with enhanced pandemic potential” in the 2024 OSTP policy that governs this category of study.
Intended meaning of the term
The file states that lawmakers used “GOF” to signal one specific risk: experiments that could make a pathogen easier to spread or more lethal. It does not extend the label to every manipulation of a microbe, only to changes that raise the chance of a wider outbreak.
This narrow framing matters because the same term has been applied in public debate to everything from routine vaccine development to high-security work on avian influenza. The document tries to fix the reference point so regulators and scientists start from the same definition.
By anchoring the label to transmissibility and virulence, the proposal also limits the scope of future reviews to pathogens already viewed as pandemic threats rather than every organism studied in a lab.
Proposed replacement language
The record recommends that the 2024 OSTP policy adopt the longer phrase “pathogen with enhanced pandemic potential” along with its accompanying definition. The change is presented as a way to sidestep years of conflicting usage.
The authors note that continued reliance on “GOF” keeps producing confusion inside review boards and among researchers who must decide whether a protocol triggers extra oversight. A single, spelled-out term is offered as the remedy.
Because the 2024 policy already addresses this category of work, inserting the new wording would require only an update to existing guidance rather than an entirely new regulatory structure.
Where the language would apply
The recommendation targets oversight boards that decide which projects need extra scrutiny before funding or approval. Under the suggested wording, only research that could enhance transmissibility or virulence would fall under the stricter lane.
Projects that study pathogens without those specific risks would remain outside the enhanced category, a distinction the document says is necessary to keep essential surveillance and countermeasure work moving.
The change would also affect how agencies describe covered research in public notices, grant solicitations, and annual reports, giving both scientists and lawmakers a shared reference point.
Board composition concerns
The same file flags that limits on prior federal service and rules treating high-risk research experience as a conflict of interest could shrink the pool of qualified reviewers. Without enough specialists, boards might struggle to judge whether a protocol truly meets the transmissibility or virulence threshold.
The document does not claim these limits have already caused errors, but it warns that excluding people with direct knowledge of the work could slow decisions or produce inconsistent outcomes.
Any terminology shift would therefore need to be paired with a reviewer roster that can apply the new definition in practice.
Potential delays to surveillance
If the definitional change is paired with slower review cycles, the file warns of knock-on effects for programs that monitor H5N1, emerging Ebola strains, and routine COVID-19 variant tracking. These efforts rely on rapid turnaround for sample analysis and reagent sharing.
The authors list cancer biology and agricultural research as additional areas that could face indirect drag if every protocol is forced through the same enhanced-oversight lane, even when no pandemic risk is present.
The recommendation therefore carries an implicit deadline: refine the language before the next cycle of surveillance grants is due.
Link to 2024 OSTP policy
The 2024 OSTP framework already requires agencies to identify research that could produce pathogens with enhanced pandemic potential. Substituting the clearer term would align statutory language with that existing requirement without expanding its reach.
The document presents the substitution as a technical fix rather than a policy expansion, aimed at reducing disputes over what counts as covered work.
Because the policy is already in force, the change could be made through updated guidance rather than new legislation, shortening the timeline for implementation.
Previous terminology disputes
Public debate over “gain of function” has often conflated basic genetic manipulation with experiments that deliberately increase harm potential. The file treats this blurring as an ongoing source of friction between regulators and laboratories.
By documenting the intended scope in the bill itself, the authors aim to give future oversight a fixed reference that cannot be stretched or narrowed by shifting political arguments.
The proposal does not resolve every past disagreement, but it supplies a concrete definition that later disputes can cite.
Effect on dual-use research governance
Researchers who study governance of high-risk or dual-use research have long asked for precise terminology that separates routine pathogen work from experiments that raise outbreak risks. The file supplies one such proposal, grounded in the transmissibility-or-virulence test.
If adopted, the wording would give institutional review boards a single yardstick when they classify proposals, reducing the chance that identical experiments receive different labels at different agencies.
The change would also give lawmakers a clearer benchmark when they request future audits or funding adjustments tied to this category of research.
Next steps for the recommendation
The document leaves open whether OSTP will accept the suggested phrasing or whether Congress will codify it in statute. Either route would require agencies to rewrite internal checklists and training materials that currently reference the older term.
Until the wording is settled, review boards continue to operate under the 2024 policy’s existing definition while watching for updates that could alter which projects trigger extra scrutiny.
The file records the proposal as one among several comments on the draft legislation, indicating that the terminology question remains active rather than settled.
Terminology as policy tool
The July 2026 release shows that the debate over what counts as gain of function is not only scientific but linguistic. By offering a single, defined replacement tied to the 2024 OSTP policy, the document gives researchers studying governance of high-risk or dual-use research a concrete reference point for future oversight. Whether that reference survives agency review will shape how quickly and consistently the next generation of pandemic-related experiments is cleared or constrained.
